$ARCT
Arcturus Therapeutics Holdings Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021055372 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q3
Revenue $2.437M $2.001M $2.333M
YoY Change 4.46% -13.82% -29.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.86M $10.04M $5.570M
YoY Change 94.97% 127.19% 43.56%
% of Gross Profit
Research & Development $45.40M $45.68M $17.70M
YoY Change 156.5% 475.01% 150.94%
% of Gross Profit
Depreciation & Amortization $289.0K $284.0K $220.0K
YoY Change 31.36% 35.24% 22.22%
% of Gross Profit
Operating Expenses $45.40M $45.68M $17.70M
YoY Change 156.5% 475.01% 150.94%
Operating Profit -$53.82M -$53.72M -$20.94M
YoY Change 157.05% 434.95% 174.92%
Interest Expense -$263.0K -$861.0K -$70.00K
YoY Change 275.71% 291.36% -138.89%
% of Operating Profit
Other Income/Expense, Net -$519.0K
YoY Change
Pretax Income -$54.08M -$54.58M -$21.00M
YoY Change 157.54% 431.98% 182.64%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$54.08M -$54.58M -$21.00M
YoY Change 157.49% 431.82% 182.58%
Net Earnings / Revenue -2219.29% -2727.69% -900.3%
Basic Earnings Per Share -$2.05
Diluted Earnings Per Share -$2.053M -$2.074M -$915.4K
COMMON SHARES
Basic Shares Outstanding 26.34M 24.39M
Diluted Shares Outstanding 26.34M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $413.9M $433.6M $307.0M
YoY Change 34.81% 218.57% 313.75%
Cash & Equivalents $413.9M $433.6M $307.0M
Short-Term Investments
Other Short-Term Assets $5.071M $2.301M $4.600M
YoY Change 10.24% -25.77% 13839.39%
Inventory
Prepaid Expenses
Receivables $2.015M $2.163M $2.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $421.0M $438.0M $314.1M
YoY Change 34.02% 208.48% 295.59%
LONG-TERM ASSETS
Property, Plant & Equipment $4.843M $3.407M $8.300M
YoY Change -41.65% -56.32% 12.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $670.0K $920.0K
YoY Change
Other Assets $2.074M $107.0K $100.0K
YoY Change 1974.0% 7.0% 0.0%
Total Long-Term Assets $13.57M $10.78M $8.400M
YoY Change 61.55% 36.39% 7.49%
TOTAL ASSETS
Total Short-Term Assets $421.0M $438.0M $314.1M
Total Long-Term Assets $13.57M $10.78M $8.400M
Total Assets $434.5M $448.8M $322.5M
YoY Change 34.74% 199.41% 269.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.265M $10.08M $6.500M
YoY Change 27.15% 129.18% 61.97%
Accrued Expenses $52.36M $42.61M $12.00M
YoY Change 336.32% 460.71% 79.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $18.48M $5.000M
YoY Change
Total Short-Term Liabilities $118.2M $70.77M $28.00M
YoY Change 322.28% 207.69% 29.1%
LONG-TERM LIABILITIES
Long-Term Debt $42.35M $56.31M $15.10M
YoY Change 180.43% 272.91% 50.76%
Other Long-Term Liabilities $14.83M $16.09M $17.80M
YoY Change -16.71% -12.57% -9.18%
Total Long-Term Liabilities $57.17M $72.40M $32.90M
YoY Change 73.77% 116.11% 228.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $118.2M $70.77M $28.00M
Total Long-Term Liabilities $57.17M $72.40M $32.90M
Total Liabilities $175.4M $143.2M $60.90M
YoY Change 188.03% 153.39% 18.67%
SHAREHOLDERS EQUITY
Retained Earnings -$308.8M -$254.7M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $259.1M $305.6M $261.6M
YoY Change
Total Liabilities & Shareholders Equity $434.5M $448.8M $322.5M
YoY Change 34.74% 199.41% 269.78%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q3
OPERATING ACTIVITIES
Net Income -$54.08M -$54.58M -$21.00M
YoY Change 157.49% 431.82% 182.58%
Depreciation, Depletion And Amortization $289.0K $284.0K $220.0K
YoY Change 31.36% 35.24% 22.22%
Cash From Operating Activities -$16.65M -$32.94M -$15.88M
YoY Change 4.87% 288.02% 459.15%
INVESTING ACTIVITIES
Capital Expenditures -$1.766M -$402.0K -$440.0K
YoY Change 301.36% -14.47% 175.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.766M -$402.0K -$440.0K
YoY Change 301.36% -14.47% 175.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 692.0K 84.00K 187.2M
YoY Change -99.63% -99.9% 778.14%
NET CHANGE
Cash From Operating Activities -16.65M -32.94M -15.88M
Cash From Investing Activities -1.766M -402.0K -440.0K
Cash From Financing Activities 692.0K 84.00K 187.2M
Net Change In Cash -17.73M -33.26M 170.9M
YoY Change -110.37% -143.4% 832.86%
FREE CASH FLOW
Cash From Operating Activities -$16.65M -$32.94M -$15.88M
Capital Expenditures -$1.766M -$402.0K -$440.0K
Free Cash Flow -$14.89M -$32.54M -$15.44M
YoY Change -3.58% 305.75% 476.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
us-gaap Interest Paid Net
InterestPaidNet
173000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1828000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
674000
arct Acquisition Of Research And Development In Process Through Issuance Of Common Stock
AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock
5000000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
670000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
645000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
506000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-54084000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
305648000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-54084000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6870000
CY2021Q3 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
515000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
259126000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
93423000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21004000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
186578000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1988000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
261630000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
396553000
us-gaap Net Income Loss
NetIncomeLoss
-165011000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
5000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21397000
arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
515000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
25792000
us-gaap Net Income Loss
NetIncomeLoss
-41044000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
261883000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1461000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
261630000
us-gaap Net Income Loss
NetIncomeLoss
-41044000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
613000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
46599000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
261883000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1461000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
515000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47786000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272944000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1045000
us-gaap Share Based Compensation
ShareBasedCompensation
3938000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-263000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
923000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1027000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
268000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3872000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7335000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4236000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36229000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1045000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47048000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
235670000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415954000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
307130000
us-gaap Interest Paid Net
InterestPaidNet
173000
CY2021Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
9200000
arct Upfront Fee And Consideration
UpfrontFeeAndConsideration
9200000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
0
CY2021Q3 arct Percentage Of Equity Interest In Joint Venture
PercentageOfEquityInterestInJointVenture
0.49
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2015000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308800000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143800000
CY2021Q3 arct Nonrefundable Upfront Payment Received
NonrefundableUpfrontPaymentReceived
40000000.0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Dividends
Dividends
0
us-gaap Dividends
Dividends
0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
413880000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
307023000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2074000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415954000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
307130000
arct Contract With Customer Asset Additions For Revenue Recognized
ContractWithCustomerAssetAdditionsForRevenueRecognized
32058000
arct Contract With Customer Asset Deductions For Cash Collections
ContractWithCustomerAssetDeductionsForCashCollections
-32168000
arct Contract With Customer Liability Additions For Advanced Billings
ContractWithCustomerLiabilityAdditionsForAdvancedBillings
42058000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-6565000
CY2020Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
6585000
CY2020Q4 arct Accrued Singapore Economic Development Board Liability
AccruedSingaporeEconomicDevelopmentBoardLiability
1761000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1483000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1630000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
66113000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2437000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6565000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7301000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8789000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6441000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3946000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3063000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4843000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6376000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2097000
CY2021Q3 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
3444000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
18482000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1250000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6870000
CY2021Q3 arct Clinical Accruals Current
ClinicalAccrualsCurrent
8910000
CY2020Q4 arct Clinical Accruals Current
ClinicalAccrualsCurrent
4067000
CY2021Q3 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
13663000
CY2020Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
3249000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52358000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20639000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6666667
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8633333
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
15300000
CY2021Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
700000
CY2020Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
200000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2000000.0
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
600000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1457223
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1514023
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1405378
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1129949
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1988000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21397000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3938000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
512000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1987000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2185000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2250000
CY2021Q3 arct Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
521000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7455000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1037000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6418000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
us-gaap Operating Lease Cost
OperatingLeaseCost
1300000

Files In Submission

Name View Source Status
0001564590-21-055372-index-headers.html Edgar Link pending
0001564590-21-055372-index.html Edgar Link pending
0001564590-21-055372.txt Edgar Link pending
0001564590-21-055372-xbrl.zip Edgar Link pending
arct-10q_20210930.htm Edgar Link pending
arct-10q_20210930_htm.xml Edgar Link completed
arct-20210930.xsd Edgar Link pending
arct-20210930_cal.xml Edgar Link unprocessable
arct-20210930_def.xml Edgar Link unprocessable
arct-20210930_lab.xml Edgar Link unprocessable
arct-20210930_pre.xml Edgar Link unprocessable
arct-ex1034_76.htm Edgar Link pending
arct-ex1035_75.htm Edgar Link pending
arct-ex311_7.htm Edgar Link pending
arct-ex312_11.htm Edgar Link pending
arct-ex321_8.htm Edgar Link pending
arct-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gf31vpass1kr000001.jpg Edgar Link pending
gf31vpass1kr000002.jpg Edgar Link pending
gm1x2pl1p1vu000001.jpg Edgar Link pending
gm1x2pl1p1vu000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending